Skip to main content
Article thumbnail
Location of Repository

Protective Effect of Perindopril on Diabetic Retinopathy Is Associated With Decreased Vascular Endothelial Growth Factor–to–Pigment Epithelium–Derived Factor Ratio: Involvement of a Mitochondria–Reactive Oxygen Species Pathway

By Zhi Zheng, Haibing Chen, Genjie Ke, Ying Fan, Haidong Zou, Xiaodong Sun, Qing Gu, Xun Xu and Patrick C.P. Ho
Topics: Original Article
Publisher: American Diabetes Association
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1999). Aiello LM: Treatment of diabetic retinopathy.
    2. (2002). Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 43:849–857,
    3. (1991). Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
    4. (2006). Araie M: Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood–retinal barrier in a streptozotocininduced diabetic model. Invest Ophthalmol Vis Sci 47:4547–4552,
    5. (2001). Biochemistry and molecular cell biology of diabetic complications.
    6. (1999). Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–258,
    7. (1997). CH: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 15:269–272,
    8. (2001). DR: Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 119:709–717,
    9. (2007). Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res 84:745–752,
    10. (2006). Galin ˜anes M: Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res 69:450–458,
    11. (2006). Grossniklaus HE: Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 12:511–517,
    12. (2006). High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes. Exp Eye Res 82:172–178,
    13. (2006). IA: Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 82:798– 806,
    14. (2003). Interleukin-1beta swiftly down-regulates UCP-2 mRNA in beta-cells by mechanisms not directly coupled to toxicity. Cytokine 23:101–107,
    15. (2008). Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Curr Eye Res 33:885–891,
    16. (1998). JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28–31,
    17. (2002). JX: Difference in ischemic regulation of vascular endothelial growth factor and pigment epitheliumderived factor in brown Norway and Sprague Dawley rats contributing to different susceptibilities to retinal neovascularization.
    18. (2009). Kintscher U: PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    19. (1961). Kuwabara T: Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 66:366–378,
    20. (2000). ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43:1360–1367,
    21. (2007). Ninkovic S: Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
    22. (2008). Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454,
    23. (2006). PC: Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp Eye Res 83:807–816,
    24. Pe ´nicaud L: Role for mitochondrial reactive oxygen species in brain lipid sensing: redox regulation of food intake.
    25. (1998). Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 139:4920–4927,
    26. (1999). PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546–555,
    27. (2006). RE: Vascular effects of TZDs: new implications. Vascul Pharmacol 45:3–18,
    28. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal 9:331–342,
    29. (2006). S: Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 79:121–129,
    30. (2007). T: Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 22:1314–1322,
    31. (2002). Tangelder GJ: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 45:203–209,
    32. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625,
    33. (2006). The role of PPARs in the microvascular dysfunction in diabetes. Vascul Pharmacol 45:54–64,
    34. (1984). Thermogenic mechanisms in brown fat. Physiol Rev 64:1–64,
    35. (2006). Tsapenko IV: Use of perindopril in the treatment of patients with diabetic retinopathy. Vestn Oftalmol 122:31–33,
    36. (1995). Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
    37. (2006). Wahli W: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58:726–741,
    38. (1999). WG: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215–222,
    39. (2008). Zheng Z: Upregulation of PEDF expression by PARP inhibition contributes to the decrease in hyperglycemia-induced apoptosis in HUVECs.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.